Your browser doesn't support javascript.
loading
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink, Hiddo J L; Jongs, Niels; Chertow, Glenn M; Langkilde, Anna Maria; McMurray, John J V; Correa-Rotter, Ricardo; Rossing, Peter; Sjöström, C David; Stefansson, Bergur V; Toto, Robert D; Wheeler, David C; Greene, Tom.
Afiliação
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; The George Institute for Global Health, Sydney, NSW, Australia. Electronic address: h.j.lambers.heerspink@umcg.nl.
  • Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Chertow GM; Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
  • Langkilde AM; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • McMurray JJV; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Correa-Rotter R; The National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico.
  • Rossing P; Steno Diabetes Center Copenhagen, Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Sjöström CD; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Stefansson BV; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Toto RD; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
  • Wheeler DC; The George Institute for Global Health, Sydney, NSW, Australia; Department of Renal Medicine, University College London, London, UK.
  • Greene T; Study Design and Biostatistics Center, University of Utah Health Sciences, Salt Lake City, UT, USA.
Lancet Diabetes Endocrinol ; 9(11): 743-754, 2021 11.
Article em En | MEDLINE | ID: mdl-34619108
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Assunto principal: Compostos Benzidrílicos / Diabetes Mellitus Tipo 2 / Insuficiência Renal Crônica / Inibidores do Transportador 2 de Sódio-Glicose / Taxa de Filtração Glomerular / Glucosídeos / Rim Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Assunto principal: Compostos Benzidrílicos / Diabetes Mellitus Tipo 2 / Insuficiência Renal Crônica / Inibidores do Transportador 2 de Sódio-Glicose / Taxa de Filtração Glomerular / Glucosídeos / Rim Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2021 Tipo de documento: Article